Monitoring of modified factor VIII and IX products.
The dawning era of novel recombinant factor VIII and factor IX concentrates, many of which have been bioengineered to achieve prolonged activity, brings with it the need to consider the most appropriate clinical laboratory approaches for potency assignment, as well as the measurement of postinfusion levels. This session will highlight the known limitations and inconsistencies between existing assay methodologies with respect to currently available products, and discuss some of the early data with respect to the novel agents.
Coagulation Laboratory, Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, UK.
S
S
Kitchen
E
E
Gray
K
K
Mertens
D000818:Animals; D001780:Blood Coagulation Tests / Q000379:methods / Q000592:standards; D005164:Factor IX / Q000494:pharmacology* / Q000627:therapeutic use*; D005169:Factor VIII / Q000494:pharmacology* / Q000627:therapeutic use*; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy; D002836:Hemophilia B / Q000097:blood / Q000188:drug therapy; D006801:Humans; D015202:Protein Engineering; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D005169:Factor VIII; D005164:Factor IX
modified FIX; modified FVIII; monitoring